Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphism and Alzheimer Disease Risk: a Meta-Analysis

Methylenetetrahydrofolate reductase (MTHFR) is key enzyme of folate/homocysteine pathway. Case control association studies on MTHFR C677T polymorphism and Alzheimer’s disease (AD) have been repeatedly performed over the last two decades, but the results are inconclusive. The aim of the present study...

Full description

Saved in:
Bibliographic Details
Published in:Molecular neurobiology 2017-03, Vol.54 (2), p.1173-1186
Main Author: Rai, Vandana
Format: Article
Language:English
Subjects:
Alzheimer Disease - diagnosis
Alzheimer Disease - epidemiology
Alzheimer Disease - genetics
Alzheimer's disease
Biomedical and Life Sciences
Biomedicine
Case-Control Studies
Cell Biology
Genetic Predisposition to Disease - epidemiology
Genetic Predisposition to Disease - genetics
Humans
Meta-analysis
Methylenetetrahydrofolate Reductase (NADPH2) - genetics
Neurobiology
Neurodegeneration
Neurology
Neurosciences
Polymorphism
Polymorphism, Genetic - genetics
Risk Factors
Systematic review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Methylenetetrahydrofolate reductase (MTHFR) is key enzyme of folate/homocysteine pathway. Case control association studies on MTHFR C677T polymorphism and Alzheimer’s disease (AD) have been repeatedly performed over the last two decades, but the results are inconclusive. The aim of the present study was to assess the risk of MTHFR C677T polymorphism for AD. Forty-one studies were identified by a search of PubMed, Google Scholar, Elsevier, and Springer Link databases, up to January 2015. Odds ratios (ORs) with corresponding 95 % confidence interval (CI) were calculated using fixed effect model or random effect model. The subgroup analyses based on ethnicity were performed. MTHFR C677T polymorphism had a significant association with susceptibility to AD in all genetic models (for T vs C OR = 1.29, 95 % CI = 1.07–1.56, p  = 0.003; for TT + CT vs CC OR = 1.29, 95 % CI = 1.19–1.40, p  = 0.0004; for TT vs CC OR = 1.31, 95 % CI = 1.16–1.48, p  = 0.001; for CT vs CC OR = 1.24, 95 % CI = 1.13–1.35, p  
ISSN:0893-7648
1559-1182
DOI:10.1007/s12035-016-9722-8